Trial Profile
Active Surveillance of Adverse Events Following Immunization Among Healthcare Workers Immunized With the Influenza Vaccine.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- 13 Aug 2012 Company (GlaxoSmithKline) added in association as reported by ClinicalTrials.gov.
- 13 Aug 2012 Actual patient number changed from 7000 to 7645 as reported by ClinicalTrials.gov.
- 25 Mar 2011 New trial record